Prevexxion RN+HVT+IBD


Infectious bursal disease and Marek's disease vaccine (live recombinant)

This medicine is authorised for use in the European Union.


Prevexxion RN+HVT+IBD is a veterinary vaccine used in one-day-old chicks to prevent death and disease and to reduce lesions caused by Marek’s disease (MD) virus (including very virulent MD virus); It is also used to prevent death, disease and lesions caused by infectious bursal disease (IBD, also known as Gumboro disease) virus.

MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs. Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body. Birds infected with MD virus can be carriers and shedders of the virus for life.

IBD is a highly contagious viral infection of young chickens that reduces their immunity (body’s ability to fight disease) and can lead to their death at 3 to 6 weeks of age. Signs of chickens infected with the disease include trembling, ruffled feathers, poor appetite, dehydration, diarrhoea and huddling.

Prevexxion RN+HVT+IBD contains cells with both a live modified strain of MD virus, serotype 1 called RN1250 that has been modified to increase its effectiveness and safety and a live modified strain of turkey herpesvirus called vHVT013-69 that has been modified to produce a protein from IBD virus.

This EPAR was last updated on 10/01/2022

Authorisation details

Product details
Prevexxion RN+HVT+IBD
Agency product number
Active substance
Live recombinant Marek’s disease virus, serotype 1, strain RN1250; Live recombinant turkey herpesvirus, expressing the VP2 protein of infectious bursal disease virus, strain vHVT013-69
International non-proprietary name (INN) or common name
Infectious bursal disease and Marek's disease vaccine (live recombinant)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

55216 Ingelheim am Rhein

Product information

20/12/2021 Prevexxion RN+HVT+IBD - EMEA/V/C/005057 - IG/1450

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for aves

  • Domestic fowl

  • avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus

Therapeutic indication

For active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by Marek’s disease (MD) virus (including very virulent MD virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (IBD) virus.

Assessment history

How useful was this page?

Add your rating